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Abstract
Background: Bone morphogenetic proteins (BMPs) are members of the TGF-beta superfamily of growth factors.
They are known for their roles in regulation of osteogenesis and developmental processes and, in recent years,
evidence has accumulated of their crucial functions in tumor biology. BMP4 and BMP7, in particular, have been
implicated in breast cancer. However, little is known about BMP target genes in the context of tumor. We explored
the effects of BMP4 and BMP7 treatment on global gene transcription in seven breast cancer cell lines during a 6-
point time series, using a whole-genome oligo microarray. Data analysis included hierarchical clustering of
differentially expressed genes, gene ontology enrichment analyses and model based clustering of temporal data.
Results: Both ligands had a strong effect on gene expression, although the response to BMP4 treatment was more
pronounced. The cellular functions most strongly affected by BMP signaling were regulation of transcription and
development. The observed transcriptional response, as well as its functional outcome, followed a temporal
sequence, with regulation of gene expression and signal transduction leading to changes in metabolism and cell
proliferation. Hierarchical clustering revealed distinct differences in the response of individual cell lines to BMPs, but
also highlighted a synexpression group of genes for both ligands. Interestingly, the majority of the genes within
these synexpression groups were shared by the two ligands, probably representing the core molecular responses
common to BMP4 and BMP7 signaling pathways.
Conclusions: All in all, we show that BMP signaling has a remarkable effect on gene transcription in breast cancer
cells and that the functions affected follow a logical temporal pattern. Our results also uncover components of the
common cellular transcriptional response to BMP4 and BMP7. Most importantly, this study provides a list of
potential novel BMP target genes relevant in breast cancer.
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Background
Bone morphogenetic proteins (BMPs) are extracellular
ligand molecules that belong to the transforming growth
factor b (TGF-b) superfamily. To date, 21 members of
the human BMP family have been identified [1]. BMPs
regulate transcription of target genes by signaling
through type I and II transmembrane serine-threonine
receptors. Binding of the ligand to the type II receptor
elicits phosphorylation of the type I receptor, which, as
a result, is able to phosphorylate other molecules and
transmit the signal. In the canonical BMP pathway, the
type I receptor phosphorylates receptor-regulated
SMAD (homologue of Drosophila Mothers Against Dec-
apentaplegic) proteins (R-SMADs, SMAD-1/5/8), which
then bind to the common mediator SMAD4; the
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regulate transcription of target genes [1]. The signals
generated by BMPs in the cell membrane may be also
transferred into the cell via ERK, JNK and p38 mitogen-
activated protein kinases (MAPK) [2,3]. Moreover, there
is crosstalk between BMP signaling and other cellular
signaling cascades, such as the Wnt, JAK/STAT and
Notch pathways [4-6].
BMPs were first identified as inducers of ectopic bone
formation in vivo [7] but were later found to be crucial
multifunctional regulators of development [8]. During
the last decade, the role of BMPs in cancer development
has gained increasing interest [9-11]. The importance of
BMP4 and BMP7 in breast cancer was highlighted in a
survey of seven BMPs: these two ligands had the highest
expression levels and were the most frequently
expressed among 22 cell lines and 39 primary tumor
samples [12]. The expression of BMP4 and BMP7 in
breast cancer also has been demonstrated in several
other reports [13-17]. Interestingly, BMP7 protein
expression in primary breast tumors has been associated
with accelerated bone metastasis formation and served
as an independent prognostic factor for early bone
metastasis in a study based on a set of 409 patient sam-
ples [15] though, with a smaller set of 67 patient sam-
ples, this association was not established [18].
The functional significance of BMP4 and BMP7 in
breast cancer has been studied predominantly through
the use of in vitro models. BMP4 was shown to inhibit
cell proliferation in a panel of breast cancer cell lines by
inducing a G1 cell cycle arrest [14]. The effects of exo-
genous BMP4 on breast cancer cell migration and inva-
sion have also been studied. For the most part, the data
suggest promotion of these cellular abilities by BMP4 in
several breast cancer cell lines and in normal breast
epithelial cells [14,19], while a study in which only
MDA-MB-231 cells were analyzed reported the opposite
phenotype [20]. For BMP7, the results from different
reports and different cell lines are more variable. In
vitro examination of BMP7 manipulation have revealed
cell line-specific effects on cell proliferation, migration
and invasion; BMP7 induces all of these parameters in
MDA-MB-231 cells and inhibits cellular proliferation in
several other cell lines [21]. In opposition, in an in vivo
xenograft mouse model of MDA-MB-231 cells, BMP7
reduced tumor growth as well as the formation and
growth of bone metastases [18].
In spite of the many years since the discovery of BMPs
and being currently a very active topic in cancer
research, little is known about their target genes in
tumor conditions. The present study was designed to
g a i nk n o w l e d g ei nt h i st o p i c ,b ye x p l o r i n gt h ee f f e c t so f
BMP4 and BMP7 signaling on gene transcription in
seven breast cancer cell lines and throughout a 6-point
time series, using a genome-wide approach. We charac-
terized the transcriptional response of breast cancer
cells to BMP signaling in an analysis that included a
temporal dimension and the comparison of different cell
lines and two BMP ligands. Finally and most impor-
tantly, we report novel potential BMP target genes rele-
vant in breast cancer.
Methods
Breast cancer cell lines
Seven breast cancer cell lines (HCC1954, MDA-MB-361,
ZR-75-30, HCC1419, SK-BR-3, MDA-MB-231 and T-
47D) were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and cultured accord-
ing to the recommended conditions except for MDA-
MB-231 and T-47D, for which the concentration of FBS
in culture media were 1% and 5%, respectively.
BMP4 and BMP7 treatments
Recombinant human BMP4 and BMP7 proteins were
purchased from R&D Systems (Minneapolis, MN).
Three cell lines (HCC1954, MDA-MB-361 and ZR-75-
30) were treated with both BMP4 (100 ng/ml) and
BMP7 (50 ng/ml) separately. HCC1419 and SK-BR-3
cell lines received only BMP4 treatment (100 ng/ml),
while MDA-MB-231 and T-47D were treated only with
BMP7 (50 ng/ml). Cells were seeded on 24-well plates,
allowed to adhere for 24 h, and treated with the BMP
ligand or vehicle for 30 min, 1 h, 3 h, 6 h, 12 h and 24
h (Figure 1A). Experiments were performed in triplicate
and collected cells were pooled.
Microarrays
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Valencia, CA) and the quality of RNA was vali-
dated using the Agilent RNA 6000 Nano Kit (Agilent
Technologies, Palo Alto, CA, USA). Total RNA (500 ng)
was used to generate fluorescent Cy-3-(vehicle treated
cells) or Cy-5-labeled cRNA (BMP4- or BMP7-treated
cells) using the Agilent Low RNA Input Fluorescence
Linear Amplification Kit (Agilent Technologies). The
labeled cRNAs were hybridized to the 44 K Whole
Human Genome oligo microarrays (Agilent Technolo-
gies) according to the manufacturer’s protocol. Microar-
ray slides were scanned (Agilent Microarray Scanner)
after hybridization, and data were extracted using the
Feature Extraction software, version A.7.5.1 (Agilent
Technologies). The microarray data has been submitted
to the GEO database (accession number GSE31605).
Data analysis
T h em i c r o a r r a yd a t aw e r ef i r s ts u b j e c t e dt ol i n e a rn o r -
malization to allow comparison between arrays. All
probes were compared to the reference sequence using
Rodriguez-Martinez et al. BMC Medical Genomics 2011, 4:80
http://www.biomedcentral.com/1755-8794/4/80
Page 2 of 16BLAST (v.2.2.23). Ensembl IDs for the probes were
obtained by examining the probe’s genomic location.
The Ensembl Homo sapiens database version 60.37e was
used. This process resulted in the annotation of 84% of
all the probes. A total of 66% of the probes mapped
uniquely to genes and 16% mapped to multiple genes.
In order to determine differentially-expressed genes,
expression data were subjected to three types of filter-
ing: cell line-specific, time point-specific and general fil-
tering. Cell line-specific filtering was done separately for
each cell line, following the criteria of a differential
expression of at least 2-fold in a minimum of one time
p o i n t .I nt h et i m ep o i n t - s p e c i f i cf i l t e r i n g ,d a t af r o m
each time point were independently filtered according
to a 2-fold expression change cutoff. General filtering
was performed on all the data from all the cell lines
together (separately for BMP4 and BMP7) following the
next criteria: probes with a differential expression of at
l e a s t3 - f o l di na tl e a s tt h r e e events and/or 2-fold in at
least four events were considered for subsequent
analysis. An event refers to any time point of any cell
line, resulting in a maximum number of 30 events (5
cell lines and 6 time points per cell line). The data sets
produced by general filtering were further hand-anno-
tated to reduce the number of probes with multiple
annotations. Uniquely annotated probes are designated
hereafter as “genes, “ whereas the terms “probe” and
“genetic element” refer to multiple annotated probes or
any data including them. The gene lists resulting from
general filtering were ranked according to the number
of events in which they showed regulation. Furthermore,
all the probes derived from general filtering were sub-
jected to hierarchical clustering using correlation
metrics, agglomerative strategy and average linkage
method.
Enrichments of gene ontology (GO) terms were per-
formed on several data sets applying Fisher’se x a c tt e s t
and using all genes present on the microarray as a refer-
ence [22]. In all the GO enrichment analyses, only
probes with unique annotation were used.
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Figure 1 Experimental workflow and numbers of differentially expressed probes (DEPs) resulting from BMP4 or BMP7 treatment.( A )
Seven breast cancer cell lines were cultured on 24-well plates, allowed to adhere for 24 h, and treated with the BMP ligand or vehicle for 30
min, 1 h, 3 h, 6 h, 12 h, and 24 h. Experiments were performed in triplicate, and collected cells were pooled. (B) The expression data from each
cell line were individually filtered according to the following criteria: differential expression of at least 2-fold at a minimum of one time point.
The number of DEPs per cell line is represented. (C) The expression data from individual time points of every cell line were filtered according to
a 2-fold cutoff in expression change. The number of DEPs per time point is shown.
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finding of clusters of genes with similar expression pro-
files was performed using MCLUST R package [24].
This method was applied to data resulting from cell
line-specific filtering. Dataw e r el o g 2 - t r a n s f o r m e da n d
scaled to unit length. In the model-based clustering
method, the clusters are considered to be groups dis-
playing multivariate distributions. Several models were
fitted to the data. The selections of the best model and
the number of clusters were made based upon maximiz-
ing Bayesian Information Criterion (BIC) values for the
specific model and number of clusters that best repre-
sented the data. The data analyses were performed
using the Anduril data analysis framework [25] and R
[26].
Results
The aim of this study was to uncover the transcriptional
responses of BMP4 and BMP7 signaling in breast can-
cer. To this end, we selected breast cancer cell lines
with low endogenous expression of BMP4 (HCC1419,
SK-BR-3), BMP7 (MDA-MB-231, T-47D) or both
(HCC1954, MDA-MB-361, ZR-75-30) [12,14] and trea-
ted them with the corresponding BMP ligand (rhBMP4
or rhBMP7) and vehicle controls (Figure 1A). Global
gene expression levels were analyzed at six different
time points from 30 min to 24 h in order to reveal the
temporal patterns of transcriptional changes.
Overall transcriptional response to BMP4 and BMP7
treatment
Due to the multidimensional nature of our data, we
used three different filtering approaches, each of them
allowing analysis from a different perspective. Cell line-
specific analysis of the expression data evidenced con-
siderable variation in the number of differentially
expressed probes (DEPs) from one cell line to another
(Figure 1B), implicating distinct differences in their tran-
scriptional response to BMPs. Further evaluation of
these results revealed that BMP4 treatment resulted in
greater amounts of DEPs than BMP7 (average number
of DEPs per cell line: 5, 469 versus 3, 898 for BMP4 and
BMP7, respectively; Figure 1B). This finding could not
be explained by the differences in cell lines used to
study the two ligands, as a similar outcome was
observed in the three lines treated with both BMP4 and
BMP7 (HCC-1954, MDA-MB-361 and ZR-75-30). Time
point-specific filtering revealed clear temporal variation
in the number of DEPs (Figure 1 C). Generally, there
was a tendency towards a greater amount of DEPs at
later time points. In order to focus our attention espe-
cially on those genes whose expression was most consis-
tently and extensively affected by BMP4 and BMP7
signaling, we performed a general filtering of the
expression data according to the following criteria: fold
change (FC) ≥ +/-3 in at least 3 events and/or FC ≥
+/-2 in at least 4 events. This resulted in the identifica-
tion of 2, 421 and 1, 263 differentially expressed gene
elements (1, 678 and 905 uniquely annotated probes)
for BMP4 and BMP7 experiments respectively, further
evidencing a more prominent effect of BMP4 than
BMP7 on gene transcription.
Unsupervised hierarchical clustering on the data sets
resulting from general filtering (BMP4 and BMP7 sepa-
rately) revealed that the samples originating from a par-
ticular cell line mainly clustered together (Figure 2),
suggesting considerable variation in the response of
individual cell lines to BMPs. The most obvious exam-
ples are MDA-MB-361, ZR-75-30, and HCC1419 (for
BMP4) as well as MDA-MB-361 and HCC1954 (for
BMP7). Clustering according to time point was an
uncommon phenomenon, but it was observed for the
samples derived from MDA-MB-231, ZR-75-30,
HCC1954 and T-47D after 30 min of BMP7 treatment
(Figure 2B). At the probe level, both BMP4 and BMP7
hierarchical trees revealed a small subset of gene ele-
ments that clustered tightly together (named clusters A
and B hereafter, Figure 2, blue boxes). However, it is
important to note that the expression of the genes in
these clusters was not altered in a similar fashion in all
the cell lines; rather, they were upregulated in some cell
lines and downregulated in others, showing diverse tem-
poral patterns. For both ligands, these clusters appeared
to dictate the division of the samples into two major
tree branches (Figure 2).
In order to obtain a general view of the cellular func-
tions regulated as a result of BMP4 and BMP7 signaling
in breast cancer cell lines, we performed a GO enrich-
ment analysis on the data sets resulting from general fil-
tering. As might have been expected, functional
categories related to regulation of transcription were
among the most highly enriched for both ligands. Addi-
tionally, genes involved in organ development were
abundantly regulated as a result of stimulation with
either ligand. In this regard, BMP4 seemed more often
to regulate genes involved in skeletal system develop-
ment (Table 1), while BMP7, on the other hand,
appeared to regulate genes involved in epithelial devel-
opment, neurogenesis and tube development (Table 2).
A common synexpression group of genes regulated in
response to BMP4 and BMP7 signaling
As mentioned above, hierarchical clustering unveiled
gene clusters A (BMP4, containing 329 probes) and B
(BMP7, 228 probes) with highly correlated expression
patterns (Figure 2, blue boxes). Interestingly, of all the
probes contained in clusters A and B, 210 (154 genes
with known and unique annotation, named group C
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Page 4 of 16hereafter, Additional file 1) were present in both clusters
and thus represent shared BMP target genes. Direct
comparisons of the expression patterns of group C
probes in the three cell lines (HCC1954, MDA-MB-361
and ZR-75-30) treated with both ligands revealed ele-
ments of similarity between BMP4 and BMP7 response
in the same cell line but high variability between differ-
ent cell lines (Figure 3). For example, these genes were
Figure 2 Unsupervised hierarchical clustering of microarray data. The data sets resulting from general filtering (2, 421 probes for (A) BMP4
and 1, 263 probes for (B) BMP7) were subjected to this analysis. For both ligands, there is an evident cluster of gene elements showing very
highly correlated expression patterns throughout the samples (gene clusters A and B, blue boxes).
Rodriguez-Martinez et al. BMC Medical Genomics 2011, 4:80
http://www.biomedcentral.com/1755-8794/4/80
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gulated in HCC1954. The GO enrichment analysis
unveiled 23 enriched biological process terms, of which
21 could be classified into two functional categories,
namely development and morphogenesis (16 terms) and
gene expression (5 terms) (Additional file 2).
Temporal patterns of transcriptional response to BMP
signaling
Model-based clustering analysis of the expression data
was performed to distinguish clusters of genes with
similar temporal profiles of expression. With this
method we identified 12 to 22 probe clusters for each
cell line and these clusters could be subsequently classi-
fied into four main categories (Tables 3 and 4 and Addi-
tional file 3). Gene elements that were first regulated at
30 min or 1 h were classified as early, 3 h or 6 h early-
intermediate, and 12 h late-intermediate responders,
regardless of their expression at later time points. Late
responders included those probes differentially
expressed exclusively at the 24 h time point. Representa-
tive examples of clusters in the different temporal cate-
gories are depicted in Figure 4 A and 4B.
We had already explored the biological functions of the
genes differentially expressed upon BMP treatment. As
we were now able to temporally classify the genes, we
became interested in evaluating whether temporal pat-
terns of expression and gene function could be related.
Therefore, we grouped the clusters from each temporal
category (early, early-intermediate, late-intermediate,
and late) and performed GO enrichment analyses on the
genes within these groups (Additional file 3). Finally,
results from the different cell lines were combined.
Although enriched GO terms were not found in every
temporal stage of every cell line, many GO terms were
enriched in the four temporal categories for BMP4 (Fig-
ure 4 C). Of all the functional terms enriched through-
out the experiments, those related to development were
especially abundant in the early and early-intermediate
phases. Terms connected with regulation of gene
expression appeared at all times, although they were less
abundant at the late stage of 24 h. Metabolism-asso-
ciated terms were also present throughout the experi-
ment, but were most prominent at late-intermediate
time points. Signal transduction appeared to be an
affected biological process in all but the late-intermedi-
ate phases; it seemed most profoundly altered during
early stages. Many terms related to cell proliferation and
DNA repair were enriched among late responder genes,
but it should be noted that all these terms emerged
from one single cell line, MDA-MB-361. The results
from BMP7 data were very limited and may be
Table 1 Enriched gene ontology categories for differentially expressed genes as a result of BMP4 treatment.
Category Number of genes p-Value
Biological process
GO:0006355: regulation of transcription, DNA-dependent 240 0.005
GO:0009888: tissue development 128 0.014
GO:0001501: skeletal system development 53 0.031
GO:0030154: cell differentiation 237 0.041
Molecular function
GO:0043565: sequence-specific DNA binding 94 0.043
GO:0003700: sequence-specific DNA binding transcription factor activity 133 0.046
Table 2 Enriched gene ontology categories for differentially expressed genes as a result of BMP7 treatment.
Category Number of genes p-Value
Biological process
GO:0030182: neuron differentiation 55 0.024
GO:0048730: epidermis morphogenesis 8 0.025
GO:0051239: regulation of multicellular organismal process 88 0.025
GO:0045944: positive regulation of transcription from RNA polymerase II promoter 42 0.028
GO:0030855: epithelial cell differentiation 24 0.031
GO:0016481: negative regulation of transcription 50 0.033
GO:0035295: tube development 32 0.042
Molecular function
GO:0043565: sequence-specific DNA binding 57 0.024
GO:0003705: RNA polymerase II transcription factor activity, enhancer binding 10 0.025
GO:0016564: transcription repressor activity 38 0.038
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lation of metabolism and gene expression among the
early-intermediate and late time categories.
Potential novel BMP target genes in breast cancer
One of the main goals of this study was to identify new
BMP4 and BMP7 target genes relevant in breast cancer.
In order to distinguish those genes most often and
ubiquitously regulated by BMP treatments, differentially
expressed genes resulting from general filtering (1, 678
and 905 for BMP4 and BMP7 experiments, respectively)
were ranked according to the number of times a gene
was up- and downregulated throughout the series of cell
lines and time points (Tables 5 and 6 and Additional
file 4). It is interesting that although the proportion of
up- and down-regulation events was roughly equal
Figure 3 Hierarchical clustering heat map of group C genes with supervised clustering at the sample level. Data from each cell line are
grouped, and time points are arranged in temporal order from left to right: 30 min, 1 h, 3 h, 6 h, 12 h and 24 h.
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induction of gene transcription clearly prevailed over
inhibition when considering the 100 top-ranked genes
(75% and 73% of the events for BMP4 and BMP7,
respectively). For BMP4, 80 genes were regulated in 10
or more events, while for BMP7, the analogous number
of genes was 29 (Tables 5 and 6). Out of the 30 possible
regulation events for a single gene (5 cell lines and 6
time points), the actual maximums were 23 events
(PTPRG; protein tyrosine phosphatase, receptor type, G)
for BMP4 and 19 events (GNRHR; gonadotropin-releas-
ing hormone receptor) for BMP7 (Tables 5 and 6); all of
these were upregulation events. As expected, several
members of the Id family of inhibitors of DNA binding,
well-known targets of BMPs [27], were strongly induced
by both BMP ligands. In addition to PTPRG and
GNRHR, other genes strongly upregulated by both
ligands included APOC2 (apolipoprotein C-II) and an
as-yet unnamed gene encoding an uncharacterized pro-
tein (C12orf42). DUSP2 (dual specificity phosphatase 2)
and MAP3K5 (mitogen-activated protein kinase kinase
kinase 5) were highly induced only by BMP4. BMP7, on
the other hand, strongly promoted the expression of
genes including PBX1 (pre-B-cell leukemia homeobox 1)
and ZSCAN4 (zinc finger and SCAN domain containing
4), which were not among the genes most intensely
regulated by BMP4.
Discussion
In recent years, it has become increasingly accepted that
the deregulation of mechanisms normally involved in
developmental processes has tumorigenic effects in adult
tissues. One example is the BMP family of growth factors,
whose function in cancer physiology has been
Table 3 Summary of the temporal clusters obtained from the analysis of BMP4 data.
Early Early-intermediate Late-intermediate Late Undetermined
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
HCC1419 2 256 1 273 8 189 6 362 3 178
(14 clusters) 5 148 4 341 11 353 7 152
10 107 14 31 9 224
12 157
13 132
Total 800 654 189 715 554
HCC1954 2 265 4 256 1 158 7 283
(12 clusters) 5 353 9 258 3 419 10 156
6 108 11 244
8 110 12 251
Total 836 1009 577 439
MDA-MB-
361
6 277 3 155 8 322 1 557 5 289
(14 clusters) 13 215 7 177 9 487 2 483 10 362
14 355 12 270 11 554 4 564
Total 847 602 1363 1604 651
SK-BR-3 1 77 2 232 3 235 4 252
(17 clusters) 6 70 10 402 7 365 5 300
11 148 14 383 8 1322
13 567 16 332 9 1104
17 51 12 95
15 508
Total 913 1349 3629 552
ZR-75-30 1 601 9 140 4 2201 8 369 2 10
(18 clusters) 5 107 10 780 14 185 11 688 3 10
12 53 18 436 16 809 6 9
15 227 79
17 1363 13 17
Total 2351 1356 3195 1057 55
Gene clusters were classified in four temporal categories (early, early-intermediate, late-intermediate and late). Clusters with unclear profiles were classified as
undetermined. The cluster ID column contains the ID number of the cluster.
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cer [9-11]. In spite of this, little is known about BMP tar-
get genes in the context of tumors. The transcriptional
responses of breast cancer cells to BMP signaling have
been studied only minimally. More precisely, the effects of
BMP2 and BMP7 treatments on transcription in MCF-7
and MDA-MB-468 breast cancer cell lines, respectively,
have been analyzed using cDNA microarrays of limited
content (from several hundreds to 14, 500 gene probes)
[28-30]. In this study, we have therefore set up an experi-
mental procedure to identify potential BMP target genes
in breast cancer by studying the effects of two BMP
ligands, BMP4 and BMP7, on genome-wide gene expres-
sion. These two BMPs were selected based on their essen-
tial role in breast cancer, which we and others have
demonstrated in recent years [9-11]. Both ligands are
highly expressed in primary breast carcinomas as well as
in breast cancer cell lines [12-14,16,17]. BMP7 expression
was also shown to be associated with early bone metastasis
[15]. Additionally, in vitro studies have implicated BMP4
and BMP7 as important regulators of proliferation and
migration of breast cancer cells [14,18,20,21,31].
Our experimental approach allowed multiple types of
analyses and revealed interesting insights into how the
Table 4 Summary of the temporal clusters obtained from the analysis of BMP7 data.
Early Early-intermediate Late-intermediate Late Undetermined
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
cluster
ID
genes/
cluster
HCC1954 2 32 4 66 3 226 1 197 6 119
(14 clusters) 5 324 12 113 10 116 13 113
7 113 14 149
83 5
9 275
11 111
Total 890 328 342 197 232
MDA-MB-231 6 97 4 41 2 175 1 335
(16 clusters) 7 27 9 120 5 321 3 512
10 108 11 101 16 144 8 140
12 125 14 147
13 52 15 85
Total 409 494 640 987
MDA-MB-361 7 240 2 177 1 379 6 252
(12 clusters) 8 193 3 235 5 328
11 258 4 230 9 58
10 336 12 73
Total 691 978 838 252
T-47D 2 767 8 212 1 183 5 1265 14 7
(14 clusters) 3 127 9 594 10 377 6 559
4 38 12 476
7 414
11 163
13 88
Total 1597 1282 560 1824 7
ZR-75-30 3 205 2 169 11 105 14 87 1 8
(22 clusters) 5 286 4 30 12 196 7 16
13 114 6 1544 9 37
15 216 8 35 17 23
20 250 10 1493 21 14
22 36 16 147
18 85
19 336
Total 1107 3839 301 87 98
Gene clusters were classified in four temporal categories (early, early-intermediate, late-intermediate and late). Clusters with unclear profiles were classified as
undetermined. The cluster ID column contains the ID number of the cluster.
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Page 9 of 16Figure 4 Time series analyses. Representative clusters from the four temporal categories are shown for BMP4 (A) and BMP7 (B). For each
cluster, the upper figure shows the levels of differential expression through the time series for every probe. The lower chart represents the
average value of differential expression for all the probes in the cluster along the time scale. The number of probes in each cluster is indicated
under the cell line name. (C) GO analyses of the four temporal categories were performed, and data from the five cell lines were combined. The
enriched GO terms for BMP4 are depicted.
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Page 10 of 16Table 5 Top most regulated genes after BMP4 signaling.
# regulated events
Gene Id Gene name Gene description Up Down Total
ENSG00000144724 PTPRG protein tyrosine phosphatase, receptor type, G 23 0 23
ENSG00000125968 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 19 0 19
ENSG00000179088 C12orf42 uncharacterized protein C12orf42 19 0 19
ENSG00000158050 DUSP2 dual specificity phosphatase 2 18 0 18
ENSG00000109163 GNRHR gonadotropin-releasing hormone receptor 18 0 18
ENSG00000234906 APOC2 apolipoprotein C-II 18 0 18
ENSG00000117318 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 17 0 17
ENSG00000115738 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 16 0 16
ENSG00000172201 ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 16 0 16
ENSG00000197442 MAP3K5 mitogen-activated protein kinase kinase kinase 5 15 0 15
ENSG00000127129 EDN2 endothelin 2 15 0 15
ENSG00000164850 GPER G protein-coupled estrogen receptor 1 15 0 15
ENSG00000181638 ZFP41 zinc finger protein 41 homolog (mouse) 15 0 15
ENSG00000181626 ANKRD62 ankyrin repeat domain 62 15 0 15
ENSG00000187957 DNER delta/notch-like EGF repeat containing 14 0 14
ENSG00000238243 OR2W3 olfactory receptor, family 2, subfamily W, member 3 14 0 14
ENSG00000164683 HEY1 hairy/enhancer-of-split related with YRPW motif 1 14 0 14
ENSG00000157322 CLEC18A C-type lectin domain family 18, member A 13 1 14
ENSG00000247097 C14orf184 Putative uncharacterized protein C14orf184 8 6 14
ENSG00000212124 TAS2R19 taste receptor, type 2, member 19 9 4 13
ENSG00000186115 CYP4F2 cytochrome P450, family 4, subfamily F, polypeptide 2 6 7 13
ENSG00000176472 ZNF575 zinc finger protein 575 7 6 13
ENSG00000181722 ZBTB20 zinc finger and BTB domain containing 20 7 6 13
ENSG00000163827 LRRC2 leucine rich repeat containing 2 12 0 12
ENSG00000214049 UCA1 urothelial cancer associated 1 12 0 12
ENSG00000132854 KANK4 KN motif and ankyrin repeat domains 4 12 0 12
ENSG00000163749 CCDC158 coiled-coil domain containing 158 12 0 12
ENSG00000100029 PES1 pescadillo homolog 1, containing BRCT domain (zebrafish) 0 12 12
ENSG00000120645 IQSEC3 IQ motif and Sec7 domain 3 0 12 12
ENSG00000122852 SFTPA1 surfactant protein A1 9 3 12
ENSG00000052802 SC4MOL sterol-C4-methyl oxidase-like 9 3 12
ENSG00000197532 OR6Y1 olfactory receptor, family 6, subfamily Y, member 1 8 4 12
ENSG00000078328 RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 8 4 12
ENSG00000185010 F8 coagulation factor VIII, procoagulant component 8 4 12
ENSG00000115756 HPCAL1 hippocalcin-like 1 8 4 12
ENSG00000122859 NEUROG3 neurogenin 3 5 7 12
ENSG00000186810 CXCR3 chemokine (C-X-C motif) receptor 3 6 6 12
ENSG00000168874 ATOH4 atonal homolog 8 (Drosophila) 11 0 11
ENSG00000040731 CDH10 cadherin 10, type 2 (T2-cadherin) 11 0 11
ENSG00000168930 TRIM49 tripartite motif-containing 49 11 0 11
ENSG00000104863 LIN7B lin-7 homolog B (C. elegans) 11 0 11
ENSG00000113391 FAM172A microRNA 2277 11 0 11
ENSG00000162614 NEXN nexilin (F actin binding protein) 11 0 11
ENSG00000120693 SMAD9 SMAD family member 9 11 0 11
ENSG00000176907 C8orf4 Uncharacterized protein C8orf4 (Thyroid cancer protein 1)(TC-1) 10 1 11
ENSG00000085224 ATRX alpha thalassemia/mental retardation syndrome X-linked 10 1 11
ENSG00000163743 RCHY1 ring finger and CHY zinc finger domain containing 1 9 2 11
ENSG00000006007 GDE1 glycerophosphodiester phosphodiesterase 1 9 2 11
ENSG00000114850 SSR3 signal sequence receptor, gamma (translocon-associated protein gamma) 9 2 11
ENSG00000109472 CPE carboxypeptidase E 9 2 11
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Page 11 of 16stimulation of BMP4 and BMP7 signaling influences the
transcriptome of breast cancer cell lines. First of all, we
showed relatively high numbers of DEPs as a result of
BMP treatments, indicating a strong impact of BMP4
and BMP7 on the cell lines studied. Moreover, the tran-
scriptional response to BMP4 was of a clearly higher
magnitude than that induced by BMP7. Another aspect
of the study was the opportunity to compare the effects
of BMP signaling between cell lines. Interestingly, clear
differences were seen in the amounts of DEPs, as well as
in their expression patterns, as revealed by hierarchical
clustering. BMP signaling pathways are regulated in a
very complex manner and at many different levels, from
the availability of BMP receptors, BMP ligands and
BMP antagonists in the extracellular compartment to
t h ep r e s e n c eo ra b s e n c eo fv a rious intracellular signal
mediators and transcriptional co-activators or co-repres-
sors [32,33]. Therefore, multiple factors influence the
outcome of BMP signaling on the transcriptional level
in a given cell. We have previously reported that all six
BMP specific receptors (ACVR1, BMPR1A, BMPR1B,
A C V R 2 A ,A C V R 2 B ,a n dB M P R 2 )a r eu n i f o r m l y
expressed among the breast cancer cell lines studied
here [12]. Similarly, we have shown that SMAD4 is
expressed and that phosphorylation of SMAD-1/5/8 is
induced in these cell lines after BMP7 and BMP4 treat-
ment [14,21]. Taken together, the expression profiles of
BMP specific receptors or the mediators of the canoni-
cal intracellular pathway do not seem to have a major
role in explaining the different transcriptional responses
in the breast cancer cells. Nevertheless, due to the com-
plexity of BMP signaling regulation, it is easy to under-
stand that different cell lines may have different
transcriptional responses to BMP stimulation. This
observation highlights the importance of testing multiple
cell lines when studying BMP signaling in cancer. An
additional finding that could be inferred from our data
is that induction of gene transcription, compared with
Table 5 Top most regulated genes after BMP4 signaling. (Continued)
ENSG00000106608 URGCP upregulator of cell proliferation 2 9 11
ENSG00000064201 TSPAN32 tetraspanin 32 8 3 11
ENSG00000212128 TAS2R13 taste receptor, type 2, member 13 8 3 11
ENSG00000092871 RFFL ring finger and FYVE-like domain containing 1 7 4 11
ENSG00000139880 CDH24 cadherin 24, type 2 4 7 11
ENSG00000039319 ZFYVE16 zinc finger, FYVE domain containing 16 4 7 11
ENSG00000206052 DOK6 docking protein 6 6 5 11
ENSG00000050165 DKK3 dickkopf homolog 3 (Xenopus laevis) 5 6 11
ENSG00000115844 DLX2 distal-less homeobox 2 10 0 10
ENSG00000178343 SHISA3 shisa homolog 3 (Xenopus laevis) 10 0 10
ENSG00000123329 ARHGAP9 Rho GTPase activating protein 9 10 0 10
ENSG00000145287 PLAC8 placenta-specific 8 10 0 10
ENSG00000187634 SAMD11 sterile alpha motif domain containing 11 10 0 10
ENSG00000167962 ZNF598 zinc finger protein 598 10 0 10
ENSG00000003509 C2orf56 Protein midA homolog, mitochondrial Precursor 8 2 10
ENSG00000143153 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 8 2 10
ENSG00000189079 ARID2 AT rich interactive domain 2 (ARID, RFX-like) 2 8 10
ENSG00000162706 CADM3 cell adhesion molecule 3 7 3 10
ENSG00000147488 ST18 suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein) 7 3 10
ENSG00000182175 RGMA RGM domain family, member A 7 3 10
ENSG00000163623 NKX6-1 NK6 homeobox 1 3 7 10
ENSG00000144559 C3orf31 MMP37-like protein, mitochondrial Precursor 6 4 10
ENSG00000153002 CPB1 carboxypeptidase B1 (tissue) 6 4 10
ENSG00000181965 NEUROG1 neurogenin 1 6 4 10
ENSG00000171564 FGB fibrinogen beta chain 6 4 10
ENSG00000132612 VPS4A vacuolar protein sorting 4 homolog A (S. cerevisiae) 6 4 10
ENSG00000183023 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 4 6 10
ENSG00000166748 AGBL1 ATP/GTP binding protein-like 1 5 5 10
ENSG00000204882 GPR20 G protein-coupled receptor 20 5 5 10
ENSG00000159216 RUNX1 runt-related transcription factor 1 5 5 10
Differentially expressed genes resulting from the general filtering of BMP4 data (1, 678) were ranked according to the number of times a gene was up- and
downregulated throughout the series of cell lines and time points. Only those genes with total rank value of at least 10 are listed.
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Page 12 of 16inhibition, was the common response among those
genes most frequently regulated by BMP4 and BMP7 in
breast cancer cells. Likewise, previous microarray-based
transcriptomic analyses of TGF-b and BMP have shown
that induction of gene expression is the predominant
response of mammalian cells to stimulation by these
growth factors [28,30,33-35].
After BMP4 and BMP7 stimulation, the microarray
analyses identified a large number of differentially
expressed genes in our panel of cell lines. To explore
the biological functions of these genes, GO enrichment
analyses were performed. These revealed very similar
results for both BMP ligands, namely, regulation of tran-
scription and developmental processes. It seems, there-
fore, that the functions most prevalently influenced by
BMP signaling in breast cancer cells do not differ
remarkably from conventional roles that BMPs possess
during development [36,37].
Synexpression groups are synchronously coexpressed
gene sets, particularly apparent during embryonic devel-
opment and in the response of cells to hormones and
growth factors [38,39]. Our analyses unveiled that treat-
ment of breast cancer cells with either BMP4 or BMP7
resulted in the coordinated expression of a group of
genes (clusters A and B, respectively). Most interest-
ingly, a considerable number of the genes in these two
synexpression groups were common for the two ligands
(group C). Moreover, our data indicated that treatment
of a cell line with either BMP4 or BMP7 results in simi-
lar transcriptional responses of group C genes. We
therefore hypothesize that group C represents molecular
responses shared by the BMP4 and BMP7 signaling
pathways. This finding prompted us to ask what func-
tions these common genes fulfill in the cell. GO enrich-
ment analysis of the genes in group C revealed that
these genes are involved in two main biological
Table 6 Top most regulated genes after BMP7 signaling.
# regulated events
Gene Id Gene name Gene description Up Down Total
ENSG00000109163 GNRHR gonadotropin-releasing hormone receptor 19 0 19
ENSG00000157322 CLEC18A C-type lectin domain family 18, member A 16 1 17
ENSG00000179088 C12orf42 Uncharacterized protein C12orf42 15 0 15
ENSG00000123329 ARHGAP9 Rho GTPase activating protein 9 14 0 14
ENSG00000144724 PTPRG protein tyrosine phosphatase, receptor type, G 14 0 14
ENSG00000185630 PBX1 pre-B-cell leukemia homeobox 1 13 0 13
ENSG00000114850 SSR3 signal sequence receptor, gamma (translocon-associated protein gamma) 9 4 13
ENSG00000186153 WWOX WW domain containing oxidoreductase 5 8 13
ENSG00000234906 APOC2 apolipoprotein C-II 12 0 12
ENSG00000180532 ZSCAN4 zinc finger and SCAN domain containing 4 12 0 12
ENSG00000144711 IQSEC1 IQ motif and Sec7 domain 1 12 0 12
ENSG00000138821 SLC39A8 solute carrier family 39 (zinc transporter), member 8 11 1 12
ENSG00000165995 CACNB2 calcium channel, voltage-dependent, beta 2 subunit 3 9 12
ENSG00000122859 NEUROG3 neurogenin 3 8 4 12
ENSG00000212128 TAS2R13 taste receptor, type 2, member 13 6 6 12
ENSG00000184999 SLC22A10 solute carrier family 22, member 10 11 0 11
ENSG00000183914 DNAH2 dynein, axonemal, heavy chain 2 11 0 11
ENSG00000125968 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 11 0 11
ENSG00000167962 ZNF598 zinc finger protein 598 10 1 11
ENSG00000181722 ZBTB20 zinc finger and BTB domain containing 20 3 8 11
ENSG00000091482 SMPX small muscle protein, X-linked 10 0 10
ENSG00000117318 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 10 0 10
ENSG00000163694 RBM47 RNA binding motif protein 47 10 0 10
ENSG00000006007 GDE1 glycerophosphodiester phosphodiesterase 1 9 1 10
ENSG00000164104 HMGB2 high-mobility group box 2 8 2 10
ENSG00000250589 DUX4 double homeobox 4 2 8 10
ENSG00000130559 CAMSAP1 calmodulin regulated spectrin-associated protein 1 3 7 10
ENSG00000166501 PRKCB protein kinase C, beta 4 6 10
ENSG00000186115 CYP4F2 cytochrome P450, family 4, subfamily F, polypeptide 2 4 6 10
Differentially expressed genes resulting from the general filtering of BMP7 data (905) were ranked according to the number of times a gene was up- and
downregulated throughout the series of cell lines and time points. Only those genes with total rank value of at least 10 are listed.
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Page 13 of 16processes, regulation of gene expression and regulation
of development and morphogenesis. These results sup-
port the notion that genes known to regulate develop-
ment also have functions that are important for the
maintenance of cancer cells.
We also studied the temporal patterns of the tran-
scriptional response after BMP treatment. The number
of DEPs showed a tendency to increase with time, a
trend previously noticed in transcriptome analysis of
TGF-b family members in murine mammary epithelial
cells and in breast cancer cells [29,35]. The DEPs could
be grouped according to their temporal pattern of
expression, varying from early to late responders. These
temporal clusters were found in every cell line, and
some of them even contained over a thousand gene ele-
ments. The next logical step was to explore whether
there was a time-dependent shift in the distribution of
gene functions. Although GO enrichment results were
not obtained for all the probe clusters of all the cell
lines, interesting features could be identified, especially
in the case of the BMP4 data. Transcriptional regulation
in the first 6 hours concentrated most notably on genes
involved in developmental processes, metabolic pro-
cesses, gene expression and signal transduction. Gene
expression was also well-represented after 12 hours,
while metabolism became by far the most prominent
function at this time point. Most interestingly, 24 hours
after BMP4 stimulation there was an evident overrepre-
sentation of genes involved in cell proliferation,
although this phenomenon was observed exclusively in
MDA-MB-361 cells. All in all, the enriched biological
functions indeed fluctuated in time and in a logical
sequence, with regulation of gene expression and signal
transduction leading to changes in metabolism and
finally to regulation of cell proliferation, a phenotype
relevant for cancer cell physiology. The fact that we did
not see enrichment of cell proliferation-associated func-
tions in more than one cell line could be due to differ-
ences in the speed of BMP signaling in different cell
lines. Even though a longer experiment certainly could
have clarified this issue, we concentrated our analysis on
the first 24 hours after BMP treatment because we were
interested primarily in the identification of BMP target
genes.
As mentioned, one of the main goals of this study was
to identify potential novel gene targets of BMP signaling
relevant in breast cancer. We provided lists of candidate
genes that are strongly and rather uniformly regulated
by BMP4 or BMP7 throughout the cell lines and time
points. Some of them, such as members of the Id family
of inhibitors of DNA binding, are well-known BMP tar-
get genes [27,29]. Id proteins are transcription factors
that regulate cell growth and differentiation [40], and all
four members of the protein family play crucial roles in
various aspects of normal and malignant breast biology
[41]. Others are newly linked, in this work, to BMP sig-
naling, and some of these genes have interesting con-
nections with tumor biology, such as PTPRG or DUSP2.
A positive feedback regulation where BMP treatment
leads to increased expression of BMP antagonists is
known to exist. In our study, no consistent expression
changes were observed for any of the known BMP
antagonists, such as noggin, gremlin, sclerostin and fol-
listatin. Previous studies have shown a wide time win-
d o wi nt h ei n d u c t i o no fe . g .n o g g i ne x p r e s s i o ni n
different tissues after BMP treatment, ranging from 1 to
48 hours [42,43]. Thus it is possible that the feedback
effect in the breast cancer cells was not evident at time
points analyzed here.
Protein tyrosine phosphatases (PTPs) are key regula-
tors of the cellular protein phosphorylation balance, cri-
tical in the control of a wide spectrum of physiological
p r o c e s s e ss u c ha sc e l lp r o l i f e ration, differentiation,
transformation, transport and locomotion. Subsequently,
aberrations in phosphorylation processes play a major
role in the pathogenesis of numerous diseases, including
cancer [44,45]. PTPRG is a receptor-type PTP impli-
cated as a candidate tumor suppressor gene in several
types of tumors, including breast cancer [46,47]. In
MCF-7 breast cancer cells, PTPRG inhibits proliferation
and anchorage-independent growth and reduces tumor
formation in a xenograft model [47,48]. Delayed cell
cycle re-entry by increasing the level of cell cycle regula-
tors p21 and p27 could explain the inhibitory effect of
PTPRG on cell growth [47]. Based on the above, upre-
gulation of PTPRG in BMP-stimulated cancer cells
could contribute to the observed BMP-induced antipro-
liferative effect [14,21]. DUSP2 also belongs to the PTP
family of phosphatases. It is a mitogen-activated protein
kinase (MAPK) phosphatase (MKP) that dephosphory-
lates both threonine and tyrosine residues within target
MAPKs leading to their deactivation. MAPK signaling
controls cellular processes such as proliferation, differ-
entiation, migration and apoptosis [48]. Therefore,
abnormal MKP activity, and hence anomalous MAPK
signaling, has important consequences for processes cri-
tical to the development and progression of human can-
cer. The role of DUSP2 in cancer has been examined in
only a few studies, and data are controversial. Overex-
pression of DUSP2 expression was found in 37 of 39
malignant effusions from serous ovarian carcinoma
patients and was associated with poor survival [49]. By
contrast, decreased DUSP2 transcript levels were
reported in cancerous breast, colon, lung, ovary, kidney
and prostate tissues, and reduced DUSP2 protein levels
were observed in cervical and colon cancer [50]. Addi-
tionally, DUSP2 suppression was associated with tumori-
genesis and malignancy in colon cancer, and DUSP2
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Page 14 of 16overexpression induced apoptosis and inhibited tumor
growth in HeLa cells in vitro and in xenograft models
[51].
Conclusions
All in all, we show that BMP4 and BMP7 have strong
effects on gene expression in breast cancer cells, and
that this transcriptional response and its functional out-
come follow a temporal sequence. Our data support the
existence of a synexpression group of regulated genes
that represent the core molecular responses shared by
BMP4 and BMP7 signaling pathways. Additionally, we
provide a list of potential novel BMP target genes rele-
vant in breast cancer.
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